| Operating segments |
The
Group is organised into business units based on its products and services, and has three reportable operating segments as follow:
| Medical
and Wellness |
|
Non-surgical
aesthetic services, surgical aesthetic services, medical consultation, health screenings, cellular therapy and research and COVID-19
testing |
| Life
Science |
|
Whole
genome sequencing and pharmacogenomics |
| Others |
|
Investment
holding and provision for management services |
Management
monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance
assessment. Segment performance is evaluated based on operating profit or loss which, in certain respects as explained in the table below,
is measured differently from operating profit or loss in the consolidated statement of profit or loss and other comprehensive income.
Group financing (including finance costs) and income taxes are managed on a group basis and are not allocated to operating segments
The
following is an analysis of the Group’s revenue and results by the operating segments.
Schedule
of operating segments
| | |
Medical
and Wellness | | |
Life
Science | | |
Others | | |
Eliminations | | |
Consolidated | |
| | |
USD | | |
USD | | |
USD | | |
USD | | |
USD | |
| | |
| | |
| | |
| | |
| | |
| |
| The Group | |
| | | |
| | | |
| | | |
| | | |
| | |
| 2025 | |
| | | |
| | | |
| | | |
| | | |
| | |
| Revenue | |
| | | |
| | | |
| | | |
| | | |
| | |
| External sales | |
| 3,353,006 | | |
| 1,824 | | |
| 16,207 | | |
| - | | |
| 3,371,037 | |
| Inter-segment sales | |
| 43,361 | | |
| 611,666 | | |
| 81,206 | | |
| (736,233 | ) | |
| - | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Total revenue | |
| 3,396,367 | | |
| 613,490 | | |
| 97,413 | | |
| (736,233 | ) | |
| 3,371,037 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Result | |
| | | |
| | | |
| | | |
| | | |
| | |
| Profit/(Loss)
from operations | |
| 32,555 | | |
| (977,212 | ) | |
| (1,536,236 | ) | |
| - | | |
| (2,480,893 | ) |
| Finance costs | |
| (22,825 | ) | |
| (6,253 | ) | |
| (19,205 | ) | |
| - | | |
| (48,283 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Profit/(Loss) before tax | |
| 9,730 | | |
| (983,465 | ) | |
| (1,555,441 | ) | |
| - | | |
| (2,529,176 | ) |
| Income tax expense | |
| (93,487 | ) | |
| (2,075 | ) | |
| - | | |
| - | | |
| (95,562 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Loss for the financial
year | |
| (83,757 | ) | |
| (985,540 | ) | |
| (1,555,441 | ) | |
| - | | |
| (2,624,738 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Segment assets | |
| 2,507,576 | | |
| 3,628,762 | | |
| 9,889,374 | | |
| (8,892,075 | ) | |
| 7,133,637 | |
| Segment liabilities | |
| 3,432,954 | | |
| 7,084,309 | | |
| 6,398,515 | | |
| (8,666,225 | ) | |
| 8,249,553 | |
| 28. |
Operating segments (Cont’d) |
| | |
Medical
and Wellness | | |
Life
Science | | |
Others | | |
Eliminations | | |
Consolidated | |
| | |
USD | | |
USD | | |
USD | | |
USD | | |
USD | |
| The Group | |
| | | |
| | | |
| | | |
| | | |
| | |
| 2025 | |
| | | |
| | | |
| | | |
| | | |
| | |
| Other information | |
| | | |
| | | |
| | | |
| | | |
| | |
| Amortisation of intangible assets | |
| - | | |
| - | | |
| 163,093 | | |
| - | | |
| 163,093 | |
| Amortisation of right-of-use assets | |
| 199,618 | | |
| 121,530 | | |
| 178,996 | | |
| - | | |
| 500,144 | |
| Additional of property, plant and equipment | |
| 35,675 | | |
| 41,989 | | |
| 6,108 | | |
| - | | |
| 83,772 | |
| Depreciation of property,
plant and equipment | |
| 58,580 | | |
| 386,024 | | |
| 20,683 | | |
| - | | |
| 465,287 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| 2024 | |
| | | |
| | | |
| | | |
| | | |
| | |
| Revenue | |
| | | |
| | | |
| | | |
| | | |
| | |
| External sales | |
| 2,390,113 | | |
| 523 | | |
| 12,916 | | |
| - | | |
| 2,403,552 | |
| Inter-segment sales | |
| 187,142 | | |
| 392,896 | | |
| 72,328 | | |
| (652,366 | ) | |
| - | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Total revenue | |
| 2,577,255 | | |
| 393,419 | | |
| 85,244 | | |
| (652,366 | ) | |
| 2,403,552 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Result | |
| | | |
| | | |
| | | |
| | | |
| | |
| Loss from operations | |
| (381,848 | ) | |
| (1,130,176 | ) | |
| (843,707 | ) | |
| - | | |
| (2,355,731 | ) |
| Finance costs | |
| (6,944 | ) | |
| (12,240 | ) | |
| (23,660 | ) | |
| - | | |
| (42,844 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Loss before tax | |
| (388,792 | ) | |
| (1,142,416 | ) | |
| (867,367 | ) | |
| - | | |
| (2,398,575 | ) |
| Income tax credit | |
| 7,414 | | |
| - | | |
| - | | |
| - | | |
| 7,414 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Loss for the financial
year | |
| (381,378 | ) | |
| (1,142,416 | ) | |
| (867,367 | ) | |
| - | | |
| (2,391,161 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Segment assets | |
| 1,888,659 | | |
| 2,893,474 | | |
| 8,462,565 | | |
| (6,543,765 | ) | |
| 6,700,933 | |
| Segment liabilities | |
| 2,676,331 | | |
| 5,194,755 | | |
| 3,762,231 | | |
| (6,383,376 | ) | |
| 5,249,941 | |
| 28. |
Operating segments (Cont’d) |
| | |
Medical
and Wellness | | |
Life
Science | | |
Others | | |
Eliminations | | |
Consolidated | |
| | |
USD | | |
USD | | |
USD | | |
USD | | |
USD | |
| The Group | |
| | | |
| | | |
| | | |
| | | |
| | |
| 2024 | |
| | | |
| | | |
| | | |
| | | |
| | |
| Other information | |
| | | |
| | | |
| | | |
| | | |
| | |
| Amortisation of intangible assets | |
| 31 | | |
| - | | |
| 44,776 | | |
| - | | |
| 44,807 | |
| Amortisation of right-of-use assets | |
| 141,762 | | |
| 117,110 | | |
| 144,147 | | |
| - | | |
| 403,019 | |
| Depreciation of property, plant and equipment | |
| 67,906 | | |
| 370,197 | | |
| 17,510 | | |
| - | | |
| 455,613 | |
| Additional of property, plant and equipment | |
| 75,773 | | |
| 42,013 | | |
| 103,531 | | |
| - | | |
| 221,317 | |
| Property, plant and
equipment written off | |
| 14,083 | | |
| - | | |
| - | | |
| - | | |
| 14,083 | |
Geographical
segments
The
Group’s revenue from contracts with customers were generated within Malaysia.
|